Antipsychotics · Second-Generation (Atypical)
Olanzapine
Brand: Zyprexa, Zyprexa Zydis, Zyprexa Relhypv
Second-generation (atypical) antipsychotic
11 cards
Want adaptive tracking?
Create a free account and every review is tracked with spaced repetition. Cards you struggle with come back sooner, and your weak areas surface automatically.
Create free account →Card Topics
risk (4)monitoring (1)interaction (1)trap (2)core (1)dosing (1)population (1)
All Cards
1.Olanzapine: why does it have the worst metabolic profile among SGAs?
2.Metabolic monitoring schedule for olanzapine.
3.Olanzapine and smoking: CYP interaction and clinical pitfall.
4.Patient on olanzapine 15mg admitted to smoke-free hospital. Day 3: excessive sedation, orthostatic hypotension. Why?
5.IM olanzapine safety concern with benzodiazepines.
6.Olanzapine: unique FDA indications not shared by most SGAs.
7.Olanzapine dose range.
8.When is olanzapine's superior efficacy justified despite metabolic risk?
9.Patient on olanzapine gains 30 lbs with fasting glucose 126, triglycerides 280. Next step?
10.What is post-injection delirium/sedation syndrome (PDSS) with olanzapine pamoate (Zyprexa Relhyprev)?
11.All antipsychotics carry a black box warning for which elderly population?
Want the full clinical reference for this medication?
Read the Olanzapine reference page →